Xenon Pharmaceuticals Investor Presentation — August 2022

Document content

NASDAQ: XENE www.xenon -pharma.comCorporate Overview

A U G U S T 2 0 2 2Forward Looking Statement/Safe Harbor

This slide presentation and the accompanying oral commentary contain forward -looking statements that involve risks, uncertaintie s and assumptions. If the risks or uncertainties

ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by suc h forward -looking statements. All statements other

than statements of historical fact could be deemed forward -looking, including, but not limited to, statements regarding research and clinical development plans and timelines; the

timing of and future results from clinical trials, including those related to XEN1101; the potential efficacy, safety profile , future development plans, addressable market, regulatory

success and commercial potential of XEN1101; the anticipated timing of IND, or IND -equivalent, submissions and the initiation of future clinical trials for XEN1101; the efficacy of

our clinical trial designs; our ability to successfully develop and achieve milestones in the XEN1101; the timing and results ofour interactions with regulators; and anticipated

enrollment in our clinical trials and the timing thereof.

These statements are based on estimates and information available to us at the time of this presentation and are not guarante es of future performance. Actual results could differ

materially from our current expectations as a result of many factors, including but not limited to: the impact of the COVID -19 p andemic on our business, research and clinical

development plans and timelines and results of operations, including impact on our clinical trial sites, collaborators, and c ontractors who act for or on our behalf, may be more

severe and more prolonged than currently anticipated; clinical trials may not demonstrate safety and efficacy of any of our o r our collaborators’ product candidates; promising

results from pre -clinical development activities or early clinical trial results may not be replicated in later clinical trials; our assumptions regarding our planned expenditures and

sufficiency of our cash to fund operations may be incorrect; our ongoing discovery and pre -clinical efforts may not yield additi onal product candidates; any of our or our

collaborators’ product candidates, including XEN1101, may fail in development, may not receive required regulatory approvals, ormay be delayed to a point where they are not

commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies m ay impose additional requirements or delay the

initiation of clinical trials; regulatory agencies may be delayed in reviewing, commenting on or approving any of our or our collaborators’ clinical development plans as a result of